TY - JOUR
T1 - Crizotinib-induced fatal fulminant liver failure
AU - van Geel, Robin M. J. M.
AU - Hendrikx, Jeroen J. M. A.
AU - Vahl, Jelmer E.
AU - van Leerdam, Monique E.
AU - van den Broek, Daan
AU - Huitema, Alwin D. R.
AU - Beijnen, Jos H.
AU - Schellens, Jan H. M.
AU - Burgers, Sjaak A.
PY - 2016/3
Y1 - 2016/3
N2 - Herein we describe a case of a 62-year-old female in good clinical condition with non-small-cell lung cancer who was treated with crizotinib. After 24 days of crizotinib therapy she presented with acute liver failure. Serum aspartate aminotransferase and alanine aminotransferase levels had increased from normal prior to crizotinib start to 2053 IU/L and 6194 IU/L, respectively. Total bilirubin and prothrombin time (PT-INR) increased up to 443 IU/L and 5.33, respectively, and symptoms of hepatic encephalopathy and hepatorenal syndrome emerged. Despite crizotinib discontinuation and intensive supportive therapy, the patient died 40 days after treatment with crizotinib was initiated due to acute liver failure with massive liver cell necrosis.
AB - Herein we describe a case of a 62-year-old female in good clinical condition with non-small-cell lung cancer who was treated with crizotinib. After 24 days of crizotinib therapy she presented with acute liver failure. Serum aspartate aminotransferase and alanine aminotransferase levels had increased from normal prior to crizotinib start to 2053 IU/L and 6194 IU/L, respectively. Total bilirubin and prothrombin time (PT-INR) increased up to 443 IU/L and 5.33, respectively, and symptoms of hepatic encephalopathy and hepatorenal syndrome emerged. Despite crizotinib discontinuation and intensive supportive therapy, the patient died 40 days after treatment with crizotinib was initiated due to acute liver failure with massive liver cell necrosis.
KW - Crizotinib
KW - Hepatotoxicity
KW - Fulminant liver failure
KW - Non-small cell lung cancer
U2 - 10.1016/j.lungcan.2015.12.010
DO - 10.1016/j.lungcan.2015.12.010
M3 - Editorial
C2 - 26898609
SN - 0169-5002
VL - 93
SP - 17
EP - 19
JO - Lung Cancer
JF - Lung Cancer
ER -